Bayer and Janssen report positive venous thromboembolism data for Xarelto

Bayer and Janssen have announced new clinical trial data showing the effectiveness of Xarelto in the treatment of venous thromboembolism (VTE).

Data from the EINSTEIN CHOICE study has demonstrated that both 10 mg and 20 mg once-daily dosages of the oral Factor Xa inhibitor significantly reduced the risk of recurrent VTE compared with aspirin in patients previously treated for pulmonary embolism or symptomatic deep vein thrombosis.

The 20 mg dose reduced the risk of recurrent VTE by 66 percent compared with aspirin 100 mg taken once daily, whilst the 10 mg cut the risk of recurrent VTE by 74 percent. Both dosages demonstrated comparable and low major bleeding rates.

Generally, patients with unprovoked VTE or ongoing risk factors see a risk of recurrence of up to ten percent in the first year if anticoagulation therapy is stopped after 3, 6 or 12 months.

Dr Joerg Moeller, member of the executive committee of Bayer's pharmaceutical division and head of development, said: "The new data from EINSTEIN CHOICE adds important additional insights on how best to provide extended protection for patients with a VTE."

Data from this study has already been submitted to the European Medicines Agency and will be filed with other regulatory bodies worldwide during the first half of 2017.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.